Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US5610281A · kind A · utility
43Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 3, 1994 |
| Grant date | Mar 11, 1997 |
| Priority date | — |
| Expiry date | May 3, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods and compositions for modulating the heterotypic adhesion between E-cadherin expressing cells and T lymphocytes. Monoclonal antibodies which specifically bind to E-cadherin and isolated peptides which mimic the binding function of E-cadherin also are provided. The antibodies and peptides are useful in screening assays to identify pharmaceutical lead compounds which are capable of modulating adhesion between T lymphocytes and E-cadherin expressing cells. Methods and pharmaceutical compositions for modifying the mucosal immune response of a subject also are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.